Business
Theralase Advances Its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia
TORONTO, ON / ACCESSWIRE / February 25, 2020 / Theralase® Technologies Inc. (" Ther...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Advances Its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova ScotiaTORONTO, ON / ACCESSWIRE / February 25, 2020 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and associated drug formulations, announced that Nova Scotia Health Authority (\"NSHA\") Research Ethics Board (\"REB\") has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (\"CIS\") and who are considered Bacillus Calmette Guerin(\"BCG\")-Unresponsive or are intolerant to BCG Therapy (\"Study II\").The Nova Scotia provincial cancer rates are among the highest in Canada. It is estimated for 2019 in Nova Scotia that 6,700 people were diagnosed with cancer, and 2,900 people died of cancer1 with bladder cancer cases counting for approximately 5% of cancer diagnosis.2The NSHA institution is affiliated with the Urology Department at Dalhousie (\"UDD\") University of Medicine, an innovative leader in urological oncology research. UDD evaluates new technologies designed to improve the lives of people suffering from urological cancers. Each year, more than 300 people are diagnosed with bladder cancer and seek attention in Nova Scotia.2 UDD doctors have extensive experience providing quality of care for bladder cancer patients while maintaining an active research role to enhance overall patient care.Dr. Ricardo Rendon, MD, FRCSC, Professor in the Department of Urology and Director of Clinical Trial of Dalhousie University in Halifax stated that \"We are excited to work with Theralase for the NMIBC clinical trial. Tackling cancer is a crucial topic and a priority for this region, and I am pleased that NSHA is able to contribute to the growth of innovative cancer research by taking part in this leading Pivotal PhotoDynamic Therapy (\"PDT\") study.\"With the addition of NSHA, the Company now has four sites open for patient enrollment and treatment, specifically, NSHA, London Health Science Centre (\"LHSC\"), University Health Network (\"UHN\") and McGill University Health Centre (\"MUHC\"). In addition, the Company has ap...